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An increasing number of mechanical assist devices, especially Left Ventricular Assist Devices 
(VAD), are being implanted for prolonged periods and as destination therapy. Some VAD patients 
require radiotherapy due to concomitant oncologic morbidities, including thoracic malignancies. 
This raises the potential of VAD malfunction via radiation-induced damage. So far, only case 
reports and small case series on radiotherapy have been published; most of them on HeartMate 
IITM (HMII, Abbott, North Chicago, IL, USA). Significantly, the effects of irradiation on the 
HeartMate 3TM (HM3, Abbott, North Chicago, IL, USA) remain undefined, despite the presence of 
controller components engineered within the pump itself.
We report the first case of a patient with a HM3 who successfully underwent stereotactic hypo-
fractionated radiotherapy due to an early stage non-small-cell lung cancer. The patient did not 
suffer from any complications; including toxicity or VAD malfunction. 
Based on this case report and on published literature, we think that performing radiotherapy after 
VAD implantation with the aid of a multidisciplinary team could be performed, but more in-vitro 
and cases series are needed to reinforce this statement.
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INTRODUCTION
The proportion of patients with VAD as destination therapy, bridge to decision as well as the 
number of older people with VAD is increasing(1). Seventy-two% of VAD implantation between 
2013 and 2016 were undertaken in patients older than 50 years and only 25% of this population 
were ultimately listed for heart transplantation(2). As the population of patients with VAD is getting 
older and their “lifetime on pump” is increasing, the number of patients developing malignancies 
is expected to rise(3). In addition, advanced heart failure itself is associated with a higher 
incidence of cancer(4). In one series, 7% (8 of 118) of patients implanted with a VAD were 
subsequently diagnosed with neoplasia within the next few years(5). In addition, cancer 
treatments themselves can lead to advanced heart failure,(6) and patients who suffer or have 
suffered from cancer cannot be listed for heart transplantation until confirmation of remission and 
stratification of risk of recurrence has been established,(7) which demands oncologic treatment 
with curative intent. These patients with severe heart failure and potentially curable or slowly 
developing neoplasia (with a life expectancy of more than two years) may be considered for VAD 
implantation(8). For those patients with at unacceptably high risk from invasive surgery and stage 
I non-small-cell lung cancer (NSCLC) or patients refusing surgery, radiotherapy is the standard of 
care(9).
While the commonest VADs implanted worldwide, HeartMate 3™ (HM3, Abbott, IL) and 
HeartWare HVAD™ (Medtronic, MN), are both centrifugal-axial flow pumps, only the HM3 has 
sensors and memory storage within the implanted pump(10).The susceptibility of the HM3 and its 
internal controller components to irradiation is unknown. 
Previous experience from other cardiac implantable electronic devices (CIEDs) suggests that 
irradiation can induce device malfunction caused by alterations in the electronic circuit,(11) 
principally on memory storage components (typically in the complementary metal oxide 
semiconductors)(12). For this reason, direct irradiation of the device is avoided. Most guidelines 
and manufacturers recommend a threshold dose of 200-400 cGy for CIEDs, although, there is no 
proven threshold dose or linear relationship regarding dose and radiation-induced damage(13), 
with even low dose scatter radiation possibly leading to life-threatening loss of device function 
(stochastic effect). For photon beam energies above 10 MV the neutron production is enhanced. 
Therefore photon beams with six to ten MV should be preferred(13,14). In modern linear 
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We report the case of a 60-year-old female patient with doxorubicin induced cardiomyopathy 
secondary to adjuvant therapy for an invasive ductal carcinoma of her right breast 12 years prior. 
Despite optimal drug therapy for heart failure, mitral valve clipping for severe secondary mitral 
valve insufficiency and the implantation of a resynchronization and defibrillator device (CRT-D), 
the patient remained symptomatic of her heart failure. During the pre-heart transplantation 
assessment, a peri-hilar mass in the middle lobe, 10 - 11 mm, was identified and biopsied, 
revealing a non-small-cell lung cancer (adenocarcinoma). In the staging positron emission 
tomography – computed tomography (PET/CT) only local disease was found, with no lymph node 
or systemic metastases. Based on the 8th edition of the American Joint Committee on Cancer 
(AJCC) TNM classification(Tumor size, Lymph Nodes affected, Metastases), thi corresponds to a 
stage IA2 (cT1b cN0 cM0) with an expected 1, 3 and 5 years overall survival (OS) of 83,4%, 
56.6%, and 41.2% based on a meta-analysis of 40 trials with a comparable treatment(16).
Before treatment planning, a new cardiac decompensation lead to significant deterioration of 
patient’s haemodynamic. After careful multidisciplinary evaluation, a semi-urgent implantation of a 
HM3 VAD was carried out. 
After evaluation of the possible treatment strategies, curatively intended radiotherapy was 
deemed to be the optimal treatment modality. The possibility of a concomitant surgical removal of 
the tumour during the implantation of the pump and other surgical options were discussed 
between thoracic and heart surgeons but rejected due to the proximality of the tumor and the 
need of anticoagulation after the VAD implantation.
Three months after VAD implantation, we proceeded with planned radiotherapy. Prior to the 
radiotherapy, tumor staging was repeated with PET/CT, showing stable disease. Subsequently, 
3-dimensional radiotherapy planning was undertaken aiming to to maximally protect the HM3, 
CRT-D and their accessories.
Stereotactic hypofractionated radiotherapy was planned on iPlan v.4.5 (Brainlab, Feldkirchen, 
Germany) with a prescribed dose of 5000 cGy in five fractions, which were delivered over 10 
days every-other day. The treatment plan consists of a coplanar arc and five coplanar intensity-
modulated beams (Figure 2) using the 6-MV photon beam on a Novalis TX linac (Varian, Palo 
Alto, California, USA). The heart, the VAD and its components were spared as much as possible 
(Table 1). 
In order to protect the intracorporal parts of the VAD, no beam through the pump was permitted. 
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driveline) were placed as far away as possible from the beam and covered with an x-ray 
protective apron (Pb 0.35 mm, Wirona AG, Niederscherli, Switzerland) (Figure 3). Although 
divergences exist in the literature regarding shielding with lead, after discussion with the 
manufacturer, we opted to use lead shielding in our protocol. 
Before, during and after each radiotherapy fraction the VAD system was tested (Table 5). 
Regarding the CRT-D, we deactivated the defibrillator using a magnet and tested the device after 
each radiotherapy fraction.
In order to detect VAD dysfunction it is imperative to monitor vital signs. Due to the lack of a pulse 
and a paced heart rhythm, we decided to use direct camera visualization coupled with cerebral 
near-infrared spectroscopy as a surrogate of hemodynamics. This technique is routinely 
employed in our institution during the perioperative phase of VAD implantation(17). During each 
radiotherapy session, a team of anaesthetists specialized in the cardiovascular field were 
available. 
The total dose could be delivered without any complications. No change in the cerebral near-
infrared spectroscopy was observed during the therapy. No malfunctions of the VAD or of the 
CRT-D was documented during or after irradiation. 
Three months after the end of the radiotherapy, surveillance PET/CT demonstrated regression of 
the tumor. The patient is planned to be followed up in line with international consensus guidelines 
for NSCLC(18).
Systematic review
Before planning the radiotherapy, a systematic review of the existing literature was performed in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) statement(19). Five databases; Medline, Google scholar, Embase, Ovid journal and 
Science direct journal were searched using the search term “mechanical support” (and 
synonyms, “HVAD”, “LVAD”) associated with “radiotherapy” (Table 4). We included all 
publications written in German, French and English. A manual search in the reference list of each 
included article was performed to search for articles not already included in the review.
Of the initial 325 unique records, we excluded 307 on the basis of the title or abstract. The 18 
eligible publications were read in detail. Nine were included for final analysis, four publications 
describing in-vitro testing (Table 2) and six publications describing case reports from a total of 









This article is protected by copyright. All rights reserved
All the in-vitro studies utilized a similar setup with a testing chamber filled of water to simulate 
both the blood and the body of the patient. A functioning VAD was submerged in the chamber 
and then irradiated. Two modalities were used: proton beam and electron beam. In total 12 VADs 
were tested using this methodology, with direct exposures up to 7560 cGy(20). No change in the 
parameters of the VADs were found during or after irradiation (Table 2). 
The in-vivo studies were more heterogeneous. The indication for implantation, the type of VAD 
and the radiation doses varied widely between cases. The highest delivered radiotherapy dose to 
a VAD patient was 5400 cGy in three fractions for a NSCLC (VAD: Mean dose 9.6 cGy, max dose 
61 cGy)(14). The maximal reported doses received directly to a VAD was 4900 cGy with a mean 
of 1922cGy for a gastroesophageal junction tumour.(14) None of the publications reported any 
complication during or after irradiation (Table 3).
Discussion
The literature on radiotherapy in patients with a mechanical assist device is scarce. Nevertheless, 
on the available evidence, radiotherapy including thoracic irradiation appears safe for patients 
with HeartMate II (HMII), HeartWare (HW) and miniaturized ventricular assist device (MVAD, 
Medtronic, MN). However, case reports may be subject to publication bias and larger cohorts are 
awaited. 
Ours is the first report of radiotherapy administration in a patient with a concomitant HM3 VAD. 
Given the change in technology to include a sensor within the HM3 pump, further information, 
such as the current case report, and further in-vitro data are warranted to demonstrate safety of 
radiotherapy for this pump system.
Here we summarize our approach for the management of radiotherapy in VAD patients with a 
special focuses on the HM3, modified from Emerson et al (14):
1. A multidisciplinary approach is mandatory for the planning and the delivery of the 
radiotherapy. Ideally, the multidisciplinary team should involve a heart failure specialist, a 
radiation oncologist, a medical oncologist (in case of a planned systemic treatment), a 
VAD-specialised nurse or perfusionist, a medical physicist and an anaesthetist.
2. For radiation planning, lower beam energies (< 10 MV) should be preferred using 
conformal radiation methods with the lowest dose possible to the VAD components as 
achievable. Because there still is an unpredictable stochastic risk for loss of function of the 
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3. Shortly before, during and after radiotherapy, especially with the HM3 device, the rapid 
response team, the cardiac surgeon and the invasive cardiologist should be aware of the 
situation and be prepared to intervene in case of device failure (such as temporary 
circulatory support device). A replacement extracorporeal controller and battery must be 
at hand, ready to be installed.
4. Monitoring of the patient should be carefully considered. One possibility is the use of 
cerebral near-infrared spectroscopy.
5. The extracorporeal controller and battery have to be secured against mechanical damage 
(e.g. collision with the radiotherapy equipment, falling down) and shielded with lead 
blanket. 
6. The VAD should be interrogated after each radiation therapy.
7. Close monitoring of the anticoagulation is advisable due to possible interaction between 
radiation therapy and clotting system(21).
CONCLUSION 
Increased implantations of VADs will result in a growing number of VAD patients requiring 
radiation therapy secondary to the development of malignancies. To the best of our knowledge, 
we have reported the first case of a patient with a new generation VAD (HM3) who successfully 
underwent stereotactic hypofractionated radiotherapy in the thoracic region without any 
malfunction of their device. In contrast to previous generations, the HM3 contains electronic 
components within the implanted pump which could theoretically make this iteration more 
vulnerable to irradiation.
This case report and the review of the available literature indicate that it is possible, with 
interdisciplinary work, to deliver radiation therapy for a thoracic malignancy in patients with a VAD 
without side effects or malfunction. More definitive comments require in-vitro studies as well as 
larger case series. Nevertheless, the stochastic nature of possible events is not predictable and 
should always be kept in mind.
CONSENT 
The patient gave a written informed consent for publication of this case and any accompanying 
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Corresponding color in Fig. 1
VAD 8 29 yellow 
Extracorporeal controller --- 0.441† See Fig. 3 (arrow)
Outflow graft 147 991 dark green
Drive line (DL) 11 34 orange
CRT-D 6 69 lime
CRT-D wires 184 3319 lime
Heart 238 3598 red
Abbreviations: CRT-D: Cardiac resynchronization therapy defibrillator
†Measured dose after first irradiation. SC was covered with an x-ray protective apron (Pb 0.35 
mm, Wirona AG, Niederscherli, Switzerland). During the first radiotherapy session, the dose 
besides the SC was measured using a pinpoint ionization chamber (0.015 cm3) (PTW, Freiburg, 
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Table 2: Existing literature on in-vitro testing of VAD’s during radiotherapy
REF VAD Test Total 
dose 
[cGy]
VAD function after 
irradiation
(22) HMII X-ray beam: 4Gy/min, 50 × 50 cm2,2,5 min, 2 
time, up to 20Gy
VAD1: 2000 No changes*
(20) HW X-ray beam: 18 MV (linear accelerator), rate 




MVAD X-ray beam: 18 MV (linear accelerator), rate 




MVAD Proton beam: 4 Gy/min, 175 MeV(cyclotron), 




(24) HW Proton beam: 5 Gy/min, 150 MeV (cyclotron) 







* Minor changes in the polymeric components of the DL
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Table 3: Existing literature on in-vivo testing of VAD’s during radiotherapy













BTT Adenocarcinoma of 
the rectum
4500 / 25 NR 425 No




2000 / 14 NR NR No
(26) HM II BTC Hodgkin’s lymphoma NR NR NR No
(27) CPS, 
Novacor
NR Squamous cell 
carcinoma on the left 
main bronchus
3500 / 5 231 538 No
HM II BTT Lung 
adenocarcinoma 
right lower lobe
5400 / 3 9.6 61 No
HM II BTT Right lung lower lobe 
and vertebral 
metastasis
NR 1423 2450 No
(14)




5040 / 28 1922 4900 No
(28) HW DT Left lung lower lobe 
(no confirmation 
biopsy with high 
complication risk)
5000 / 5 45 698 No
VAD: Ventricular Assist device, BTC: Bridge to Candidacy, BTT: Bridge to transplant, BTR: Bridge to 
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Table 4: research term used in the different databased
Search engine Data base modality Research query 
Pubmed Medline MeSH terms, 
title and abstract
Heart, Artificial and Radiotherapy








Free text ““VAD” OR “LVAD” OR “HVAD” and 
“Radiotherapy” "
Scopus Scopus Free text “VAD” OR “LVAD” OR “HVAD” and 
“Radiotherapy”
Googlescholar Googlescholar Free text "Radiotherapy" "VAD" OR OR 
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After two radiation 
therapy




5’050 5’050 5’050 5’000*
Flow [l/min] 4.1 4.1 4.1 4.0
PI 4.2 4.3 4.3 3.7
Energy 
[watt]
3.6 3.6 3.6 3.4










This article is protected by copyright. All rights reserved
FIGURES
Figure 1.: A – C. Anatomic relationship between the VAD, the ICD and the tumour
A. VAD and heart/large vessels B. and tumor and CRT-D/wires C. and lungs 
Colors: Yellow: Flow pump; Dark green: Outflow graft; Orange: Drive line; Red: LV/RV/LA/RA; 
Light red: Aorta; Blue: Pulmonary veins/VCI/VCS; Lime: CRT-D/Wires; White: Lungs; Black/red 
contoured with an arrow: Tumor
Abbreviations: VAD: ventricular assist device; CRT-D: Cardiac resynchronization therapy 
defibrillator
Figure 2.: coplanar intensity-modulated beams
A. Radiation plan with a coplanar arc (arrowheads Δ) and five coplanar IMRT beams (asterisk *) 
using the 6-MV SRS photon beam.
B. Dose color wash isodoses of the treatment volume in coronal view with the corresponding 
color bar (in cGy). This reveals that the pump (yellow) is outside the beams.
C. Dose color wash isodoses of the treatment volume in axial view at the level of the tumor and 
the coplanar arc.
Colors for A and B: Red: Tumor; Yellow: Flow pump; Orange: External cable; Green: Outflow 
graft; Light green: CRT-D, White: Heart, 
Abbreviations: IMRT: intensity-modulated radiation therapy; SRS: stereotactic radiosurgery
Figure 3: Treatment positioning and placement of the extracorporeal Extracorporeal controller
White arrow: The shielding of the Extracorporeal controller 
Figure 4: PRISMA flow chart
* An article and a poster from same authors described the exact same case. 
** One of the publications describes an in-vivo and in-vitro study
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